After spending more than six months at a nothing better than a mediocre three-star rank, DepoMed
With two drugs already on the market and a growing pipeline, CAPS members have grown more bullish on DepoMed's stock along with some of its recent developments. The company reported a 56% jump in first-quarter revenue, with help from strong sales of its diabetes drug Glumetza, which is marketed with promotional partner Santarus
The company's shares have been fighting their way back after a taking hit earlier this year related to the FDA's rejection of XenoPort's and GlaxoSmithKline's
DepoMed has also established other licensing partnerships like its deal with Merck
Do you think DepoMed deserves its improved status? Add your thoughts in the comments box below on this page, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.
The Motley Fool Stock Advisor service looks for companies with strong management poised to beat the market over the long haul. To see all the stocks that have helped Tom and David Gardner beat the market by 61 points on average, take a free 30-day trial.
Fool contributor Dave Mock recently upgraded his bathtub toy set with a brand new rubber ducky. He owns shares of Pfizer. Covidien and Pfizer are Inside Value choices. The Fool owns shares of GlaxoSmithKline. The Fool's disclosure policy lives large with a big SUV and outsized ego to match.
More from The Motley Fool
Depomed Executes an Exit Strategy for Its Opioid Drug
The company hopes a restructuring of its business can help it get back on its feet.
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.
Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
These stocks helped drag the market lower. Find out why.